C5orf46: a promising prognosis risk indicator with implication in the remodeling of KIRC and pan-cancer tumor microenvironments
-
By
-
Lei Miao
-
Fei Wang
-
Xuzhi Wang
-
Huijun Yang
-
Jiayao Li
-
Siying Liu
-
Ningning Shen
-
Zhiqing Yang
-
Lifang Gao
-
Wenxia Ma
-
Chen Wang
-
May 4, 2026
-
Clinical Scorecard: C5orf46: An Emerging Prognostic Biomarker Influencing KIRC and Pan-Cancer Tumor Microenvironment Dynamics
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Regulation of tumor microenvironment dynamics, including angiogenesis, immune infiltration, ECM degradation, and potential therapeutic targeting. |
| Target Population | |
| Care Setting | |
Key Highlights
- C5orf46 is upregulated in various cancers, with the highest expression in KIRC.
- Higher C5orf46 expression correlates with worse overall survival and shorter recurrence-free survival.
- C5orf46 is associated with critical cancer traits such as angiogenesis and immune infiltration.
- The gene's expression is influenced by DNA methylation.
- C5orf46 may impact sensitivity to chemotherapy-related drugs and may serve as a therapeutic target.
Guideline-Based Recommendations
Diagnosis
Management
- Consider C5orf46 as a potential therapeutic target in cancer treatment strategies, including immunotherapy and chemotherapy.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
C5orf46 may influence the effectiveness of immunotherapy and chemotherapy, warranting further investigation.
Clinical Best Practices
- Incorporate C5orf46 analysis in routine cancer biomarker assessments and clinical decision-making.
References
